review

Organizations across industries face challenges with high volumes of multi-page documents that require intelligent processing to extract accurate information. Although automation has improved this process, human expertise is still needed in specific scenarios to verify data accuracy and quality. In March 2025, AWS launched Amazon Bedrock Data Automation, which enablesContinue Reading

Generative AI question-answering applications are pushing the boundaries of enterprise productivity. These assistants can be powered by various backend architectures including Retrieval Augmented Generation (RAG), agentic workflows, fine-tuned large language models (LLMs), or a combination of these techniques. However, building and deploying trustworthy AI assistants requires a robust ground truthContinue Reading

This post is co-written with Sneha Godbole and Kate Riordan from Verisk. Verisk (Nasdaq: VRSK) is a leading strategic data analytics and technology partner to the global insurance industry. It empowers its customers to strengthen operating efficiency, improve underwriting and claims outcomes, combat fraud, and make informed decisions about globalContinue Reading

spawns Hutchmed (NASDAQ:HCM) ADRs traded higher on Friday after regulators in China agreed to review the company’s lymphoma therapy tazemetostat, developed and sold in partnership with Ipsen (OTCPK:IPSEY). China’s National Medical Products Administration (NMPA) granted priority review for the new drug application (NDA) targeting adults with relapsed or refractory (“R/R”)Continue Reading

Grandbrothers/iStock Editorial via Getty Images Ionis Pharmaceuticals (NASDAQ:IONS) traded higher Tuesday after the U.S. FDA accepted to review a marketing application for its anti-lipid therapy olezarsen, targeted at a rare genetic condition known as familial chylomicronemia syndrome (FCA). Granting priority review for Ionis’ (IONS) New Drug Application (NDA) for olezarsen,Continue Reading